Ramjiawan Ryan, Chung David, Fidel Maximilian G, Dhillon Harliv, Bal Dhiraj S, Pandian Alagarsamy, Bard Robert, Nayak Jasmir G, Patel Premal
Section of Urology, Department of Surgery, University of Manitoba, Winnipeg, MB, Canada.
Max Rady College of Medicine, University of Manitoba, Winnipeg, MB, Canada.
Can Urol Assoc J. 2025 Jan;19(1):E18-E24. doi: 10.5489/cuaj.8808.
Urinary retention secondary to benign prostatic hyperplasia (BPH) requiring catheterization is a prevalent and morbid condition. The objective of this study was to evaluate the real-world efficacy and safety of Rezūm as the primary treatment of catheter-dependent urinary retention.
A single-center, retrospective study analyzed patients with catheter-dependent urinary retention secondary to BPH who were treated with Rezūm between April 2022 and April 2024. Standardized postoperative followup was required for inclusion. Patient demographics, medication use, volume drained at time of urinary retention, catheter-free status, complications, and postoperative International Prostate Symptom Score (IPSS) was collected.
A total of 53 patients were included. Mean age was 73.4 years (standard deviation 9.4), and the mean Charlson comorbidity index score was 3.7. The baseline mean prostate volume was 81.7 (range 33-179) mL. Patients were catheter-dependent for an average of 225 (range 30-1821) days prior to surgical intervention. Average followup time was 10.2 months. Of the 53 patients treated, 42 (79%) patients were able to become catheter-free after treatment. Twenty-six (49%) patients failed their initial trial of void at 14 days postoperatively; 11% (n=6) of patients experienced hematuria with one admitted to hospital due to hematuria/clot retention. There were no Clavien-Dindo >3 complications. Only retention volume ≥1 L was a significant independent predictor of treatment failure on univariate and multivariate logistic regression analysis.
Rezūm effectively treated catheter-dependent urinary retention. Given the simplicity of treatment, accessibility, and minimal anesthetic requirements, providers should consider Rezūm to minimize indwelling catheter-related morbidity for catheter-dependant patients.
因良性前列腺增生（BPH）导致的需要导尿的尿潴留是一种常见且病态的情况。本研究的目的是评估 Rezūm 作为依赖导尿管的尿潴留主要治疗方法的实际疗效和安全性。
一项单中心回顾性研究分析了 2022 年 4 月至 2024 年 4 月期间接受 Rezūm 治疗的因 BPH 导致依赖导尿管的尿潴留患者。纳入标准为术后进行标准化随访。收集了患者的人口统计学数据、用药情况、尿潴留时排出的尿量、无导尿管状态、并发症以及术后国际前列腺症状评分（IPSS）。
共纳入 53 例患者。平均年龄为 73.4 岁（标准差 9.4），平均 Charlson 合并症指数评分为 3.7。基线时平均前列腺体积为 81.7（范围 33 - 179）mL。手术干预前患者平均依赖导尿管 225（范围 30 - 1821）天。平均随访时间为 10.2 个月。在接受治疗的 53 例患者中，42（79%）例患者治疗后能够不再依赖导尿管。26（49%）例患者术后 14 天首次排尿试验失败；11%（n = 6）的患者出现血尿，其中 1 例因血尿/血凝块潴留入院。无 Clavien-Dindo >3 级并发症。在单因素和多因素逻辑回归分析中，仅潴留量≥1 L 是治疗失败的显著独立预测因素。
Rezūm 有效治疗了依赖导尿管的尿潴留。鉴于治疗的简便性、可及性和最低麻醉要求，医疗服务提供者应考虑使用 Rezūm，以将依赖导尿管患者与留置导尿管相关的发病率降至最低。
